Abstract 1451P
Background
In the randomized, phase 3 KEYNOTE-585 study (NCT03221426), perioperative pembro + chemo vs placebo (pbo) + chemo significantly improved pCR (diff, 10.9%; 95% CI, 7.5-14.8; P<0.00001), with no new safety signals in patients (pts) with locally advanced G/GEJ cancer. Prespecified exploratory PROs are reported.
Methods
Eligible adults had untreated locally advanced resectable G/GEJ adenocarcinoma and ECOG PS of 0 or 1. Pts were randomly assigned 1:1 to receive neoadjuvant 200 mg pembro IV + chemo or pbo + chemo Q3W for 3 cycles, then surgery, adjuvant pembro + chemo or pbo + chemo Q3W for 3 cycles, then adjuvant pembro or pbo alone Q3W for 11 cycles. The main cohort had pembro or pbo + cisplatin-based doublet chemo; the safety cohort had pembro or pbo + FLOT. Health-related quality of life (HRQoL) was evaluated in pts who had ≥1 dose of treatment and ≥1 PRO assessment. PRO end points were least squares mean (LSM) change from baseline to week 6 (neoadjuvant) or week 39 (adjuvant) in subscales of EORTC QLQ-C30, EORTC QLQ-STO22, and EQ-5D-5L VAS. Week 6 was the only analysis time in the neoadjuvant phase; week 39 was the latest time in the adjuvant phase when completion was ≥60% and compliance was ≥80%. Improvement was a positive (EORTC QLQ-C30, EQ-5D-5L VAS) or negative (EORTC QLQ-STO22) LSM change. Database cutoff was Feb 16, 2024.
Results
The PRO analysis comprised 980 pts (pembro + chemo, n=490; pbo + chemo, n=490). Median follow-up was 58.6 months (range, 36.7-75.8) for pembro + chemo and 58.5 (36.7-75.8) for pbo + chemo. LSM changes from baseline in the combined cohorts are in the table. Table: 1451P
Change from baselinea in LSM (95% CI) to week 6 (neoadjuvant) or 39 (adjuvant)
Neoadjuvant pembro + chemo | Neoadjuvant pbo + chemo | Adjuvant pembro + chemo | Adjuvant pbo + chemo | |
QLQ-C30 GHS/QoL | n=489 | n=488 | n=374 | n=371 |
–1.68 (–3.73 to 0.36) | –4.73 (–6.79 to –2.68) | 4.23 (1.99-6.47) | 4.12 (1.94-6.31) | |
QLQ-STO22 pain scale | n=487 | n=486 | n=374 | n=371 |
–3.14 (–4.95 to –1.34) | –1.35 (–3.16 to 0.46) | –5.30 (–7.45 to –3.15) | –3.03 (–5.13 to –0.93) | |
EQ-5D-5L VAS | n=489 | n=490 | n=373 | n = 371 |
–2.28 (–3.86 to –0.70) | –3.08 (–4.67 to –1.49) | 3.52 (1.86-5.18) | 3.37 (1.75-5.00) |
aInitiation of therapy (neoadjuvant) or surgery (adjuvant).
Conclusions
Pembro + chemo did not worsen HRQoL vs pbo + chemo for pts with untreated locally advanced resectable G/GEJ cancer enrolled in KEYNOTE-585. Combined with the safety and efficacy results from KEYNOTE-585, HRQoL data support continued exploration of perioperative pembro combinations in these pts.
Clinical trial identification
NCT03221426.
Editorial acknowledgement
Medical writing assistance was provided by Shane Walton, PhD, CMPP, and Holly C. Cappelli, PhD, CMPP, of ApotheCom (Yardley, PA, USA).
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
K. Shitara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Takeda, Ono Pharmaceutical, MSD, Novartis, Daiichi Sankyo, Amgen, Guardant Health Japan Corp, Astellas Pharma Inc., Astellas, Bayer, AstraZeneca, Zymeworks Biopharmaceuticals Inc., ALX Oncology Inc.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Astellas, Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen, PRA Health Sciences. S.Y. Rha: Financial Interests, Personal, Advisory Board: Indivumed, Amgen, LG biochemical, Astellas, beringer Ingelheim; Financial Interests, Personal, Invited Speaker: MSD, Daiichi Sankyo; Financial Interests, Personal, Steering Committee Member: Amgen; Financial Interests, Institutional, Funding: MSD, Lilly; Financial Interests, Institutional, Research Grant: BMS, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Indivumed, AstraZeneca; Financial Interests, Other, Drug supply for clinical trial: Merck; Financial Interests, Institutional, Coordinating PI, Drug supply for clincal trial: MSD; Financial Interests, Institutional, Local PI, drug supply for clinical trial: Zymeworks; Financial Interests, Institutional, Local PI, drug supply for clincial trial: BeiGene; Financial Interests, Local PI: Roche. L.S. Wyrwicz: Financial Interests, Personal, Advisory Role: GSK, Servier; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel: Servier; Financial Interests, Personal, Other, Honoraria: BeiGene, Bristol Myers Squibb, MSD. T. Oshima: Financial Interests, Personal, Invited Speaker: Taiho, Astellas; Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Other, research grant: Taiho, Kyowa Kirin, Chugai, Nihon Kayaku. M. Osipov: Non-Financial Interests, Personal, Principal Investigator: Leningrad Regional Clinical Hospital. H. Yasui: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Chugai Pharma, Bristol Myers Squibb, Daiichi Sankyo, Terumo, Eli Lilly Japan, Merck Biopharma, Yakult Honsha, Bayer Yakuhin, Takeda Pharmaceutical; Financial Interests, Personal, Advisory Board: Ono Pharmaceutical; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, Ono Pharmaceutical, Astellas Pharma, Amgen, AstraZeneca. S. Al-Batran: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, MSD Sharp & Dohme; Financial Interests, Personal, Invited Speaker: MCI Deutschland GmbH; Financial Interests, Personal, Ownership Interest, CEO: Institut für Klinische Krebsforschung IKF GmbH; Financial Interests, Institutional, Research Grant: Sanofi, Roche, Celgene, Lilly, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, MSD Sharp & Dohme, AstraZeneca, German Cancer Aid (Krebshilfe), German Research Foundation, Federal Ministry of Education and Research. M. Di Bartolomeo: Financial Interests, Institutional, Advisory Board: MSD, Lilly Spa, BMS; Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Institutional, Research Grant: Lilly Spa. S. Lonardi: Financial Interests, Personal, Advisory Board: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, MSD, Incyte, Daiichi Sankyo, Bristol Myers Squibb, Astellas, GSK, Takeda, Bayer, Rottapharm; Financial Interests, Personal, Invited Speaker: Pierre Fabre, GSK, Roche, Servier, Amgen, Bristol Myers Squibb, Incyte, Lilly, Merck Serono, MSD, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, Bristol Myers Squibb; Non-Financial Interests, Member of Board of Directors, Italian No-Profit Oncology Research Foundation supporting academic Clinical trials: GONO Foundation. Y. Guan: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. A. Valderrama: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. C. Shih: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc.; Financial Interests, Personal, Proprietary Information: Merck & Co., Inc. X. Fang: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. Y. Bang: Financial Interests, Personal, Advisory Role: Astellas, Amgen, Hanmi, Daewong, SK Biopharm. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18
1475TiP - Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION)
Presenter: Bei-Bei Chen
Session: Poster session 18